Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Stagg

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Plos One|July 14, 2015
A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate CancerMarilyne Labrie, Maria Vladoiu, Bruno G Leclerc, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseJohn Stagg, Janelle Sharkey, Sandra Pommey, et al.
Cancer Research|February 5, 2011
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasisJohn Stagg, Upulie Divisekera, Helene Duret, et al.
Cancer Research|June 5, 2007
Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinomaShayna E A Street, Nadeen Zerafa, Manuela Iezzi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerSherene Loi, Sandra Pommey, Benjamin Haibe-Kains, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisJohn Stagg, Upulie Divisekera, Nicole McLaughlin, et al.
Cancer Research|September 18, 2002
In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumorsDelphine Duguay, François Mercier, John Stagg, et al.
Cancers|July 9, 2022
CD73 Promotes Chronic Lymphocytic LeukemiaDavid Allard, Pavel Chrobak, Yacine Bareche, et al.
Oncoimmunology|May 6, 2015
Co-blockade of immune checkpoints and adenosine A<sub>2A</sub> receptor suppresses metastasisArabella Young, Deepak Mittal, Kimberley Stannard, et al.
Neoplasia (New York, N.Y.)|June 6, 2017
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor MicroenvironmentMelanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Plos One|July 14, 2015
A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate CancerMarilyne Labrie, Maria Vladoiu, Bruno G Leclerc, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2008
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseJohn Stagg, Janelle Sharkey, Sandra Pommey, et al.
Cancer Research|February 5, 2011
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasisJohn Stagg, Upulie Divisekera, Helene Duret, et al.
Cancer Research|June 5, 2007
Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinomaShayna E A Street, Nadeen Zerafa, Manuela Iezzi, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerSherene Loi, Sandra Pommey, Benjamin Haibe-Kains, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisJohn Stagg, Upulie Divisekera, Nicole McLaughlin, et al.
Cancer Research|September 18, 2002
In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumorsDelphine Duguay, François Mercier, John Stagg, et al.
Cancers|July 9, 2022
CD73 Promotes Chronic Lymphocytic LeukemiaDavid Allard, Pavel Chrobak, Yacine Bareche, et al.
Oncoimmunology|May 6, 2015
Co-blockade of immune checkpoints and adenosine A<sub>2A</sub> receptor suppresses metastasisArabella Young, Deepak Mittal, Kimberley Stannard, et al.
Neoplasia (New York, N.Y.)|June 6, 2017
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor MicroenvironmentMelanie Mediavilla-Varela, Julio Castro, Alberto Chiappori, et al.
Pageof 11